Literature DB >> 1238394

Human prothrombin activation.

M R Downing, R J Butkowski, M M Clark, K G Mann.   

Abstract

Human prothrombin has been purified from American Red Cross Factor IX concentrates. Studies of the activation of the human prothrombin with the use of sodium dodecyl sulfate electrophoretic analysis of activation products indicated that human prothrombin activation is similar to bovine prothrombin activation. Molecular weight analysis of human prothrombin and intermediated by sodium dodecyl sulfate co-electrophoresis with bovine prothrombin and its intermediates resulted in molecular weights of 70,000 for prothrombin, 51,000 for intermediate 1, 41,000 for intermediate 2, 23,000 for intermediate 3, and 13,000 for intermediate 4. Amino acid compositions of human prothrombin and intermediates are similar to those for bovine prothrombin and intermediates. NH2-terminal sequence studies of human prothrombin, intermediates, and alpha-thrombin A and B chains placed the intermediates in the parent human prothrombin molecule as described for the bovine system. Intermediate 3 is the NH2-terminal of prothrombin, and intermediate 1 is the COOH-terminal segment of the zymogen. Intermediate 4 is the NH2-terminal of intermediate 1. Intermediate 2', the immediate precursor of alpha-thrombin, is the COOH-terminal segment of intermediate 1. In general, a high degree of homology in the primary structure of prothrombin and intermediates was observed between the human and bovine system. The NH2-terminal sequences of human intermediate 2' and alpha-thrombin A chain are identical. However, human intermediate 2' isolated in a manner identical with that used for the isolation of bovine intermediate 2 is homologous with bovine intermediate 2, beginning with residue 14.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1238394

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

1.  Studies of Factors V and VIII:C in an animal model of disseminated intravascular coagulation.

Authors:  A R Giles; M E Nesheim; K G Mann
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

2.  Factor V (Quebec): a bleeding diathesis associated with a qualitative platelet Factor V deficiency.

Authors:  P B Tracy; A R Giles; K G Mann; L L Eide; H Hoogendoorn; G E Rivard
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

3.  Prothrombinase complex assembly on the platelet surface is mediated through the 74,000-dalton component of factor Va.

Authors:  P B Tracy; K G Mann
Journal:  Proc Natl Acad Sci U S A       Date:  1983-04       Impact factor: 11.205

4.  The isomorphous structures of prethrombin2, hirugen-, and PPACK-thrombin: changes accompanying activation and exosite binding to thrombin.

Authors:  J Vijayalakshmi; K P Padmanabhan; K G Mann; A Tulinsky
Journal:  Protein Sci       Date:  1994-12       Impact factor: 6.725

5.  Structure-function relationships in human alpha- and gamma-thrombins.

Authors:  L J Berliner
Journal:  Mol Cell Biochem       Date:  1984       Impact factor: 3.396

6.  A dimeric form of prothrombin on membrane surfaces.

Authors:  P J Anderson
Journal:  Biochem J       Date:  1998-12-15       Impact factor: 3.857

7.  Fate of membrane-bound reactants and products during the activation of human prothrombin by prothrombinase.

Authors:  Parvathi Kamath; Sriram Krishnaswamy
Journal:  J Biol Chem       Date:  2008-09-02       Impact factor: 5.157

8.  Fourier transform infrared spectroscopic study of Ca2+ and membrane-induced secondary structural changes in bovine prothrombin and prothrombin fragment 1.

Authors:  J R Wu; B R Lentz
Journal:  Biophys J       Date:  1991-07       Impact factor: 4.033

9.  Relationship between platelet secretion and prothrombin cleavage in native whole blood.

Authors:  M E Rybak; H K Lau; B Tomkins; R D Rosenberg; R I Handin
Journal:  J Clin Invest       Date:  1981-08       Impact factor: 14.808

10.  The measurement of thrombin in clotting blood by radioimmunoassay.

Authors:  M A Shuman; P W Majerus
Journal:  J Clin Invest       Date:  1976-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.